Loading...
Loading...
ZYME| Name | Value |
|---|---|
| Revenues | 16.9M |
| Cost of Revenue | 25.2M |
| Gross Profit | -8.3M |
| Operating Expense | 40.3M |
| Operating I/L | -23.4M |
| Other Income/Expense | 4.2M |
| Interest Income | 5.0M |
| Pretax | -19.2M |
| Income Tax Expense | -4.7M |
| Net Income/Loss | -14.5M |
Zymeworks Inc. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of biotherapeutics for cancer treatment. The company's lead product candidates, zanidatamab and ZW49, are in various stages of clinical trials for the treatment of different types of cancer. Zymeworks generates revenue through strategic partnerships with major pharmaceutical companies such as Merck, Eli Lilly, Bristol-Myers Squibb, and others, as well as through licensing and research collaborations with industry leaders. The company's focus on developing novel bispecific antibodies and antibody-drug conjugates positions it at the forefront of innovative cancer therapies.
